These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32010957)

  • 21. Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy.
    Chao YK; Chang CB; Chang YC; Chan SC; Chiu CH; Ng SH; Hsieh JC; Wang JH
    Cancer Imaging; 2023 Nov; 23(1):109. PubMed ID: 37932848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining the radiomic features and traditional parameters of
    Chen YH; Lue KH; Chu SC; Chang BS; Wang LY; Liu DW; Liu SH; Chao YK; Chan SC
    Ann Nucl Med; 2019 Sep; 33(9):657-670. PubMed ID: 31218571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma.
    Bütof R; Hofheinz F; Zöphel K; Stadelmann T; Schmollack J; Jentsch C; Löck S; Kotzerke J; Baumann M; van den Hoff J
    J Nucl Med; 2015 Aug; 56(8):1150-6. PubMed ID: 26089549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
    J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
    Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
    Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment Individualization.
    Zschaeck S; Weingärtner J; Lombardo E; Marschner S; Hajiyianni M; Beck M; Zips D; Li Y; Lin Q; Amthauer H; Troost EGC; van den Hoff J; Budach V; Kotzerke J; Ferentinos K; Karagiannis E; Kaul D; Gregoire V; Holzgreve A; Albert NL; Nikulin P; Bachmann M; Kopka K; Krause M; Baumann M; Kazmierska J; Cegla P; Cholewinski W; Strouthos I; Zöphel K; Majchrzak E; Landry G; Belka C; Stromberger C; Hofheinz F
    Front Oncol; 2022; 12():870319. PubMed ID: 35756665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
    Onal C; Torun N; Guler OC; Yildirim BA
    Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan.
    Huang JW; Yeh HL; Hsu CP; Lu YY; Chuang CY; Lin JC; Lin JF; Chang CF
    J Chin Med Assoc; 2015 Apr; 78(4):229-34. PubMed ID: 25557468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer.
    Atsumi K; Nakamura K; Abe K; Hirakawa M; Shioyama Y; Sasaki T; Baba S; Isoda T; Ohga S; Yoshitake T; Shinoto M; Asai K; Honda H
    J Radiat Res; 2013 Sep; 54(5):890-8. PubMed ID: 23520267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-chemoradiotherapy FDG PET with qualitative interpretation criteria for outcome stratification in esophageal squamous cell carcinoma.
    Huang YC; Li SH; Lu HI; Hsu CC; Wang YM; Lin WC; Chen CJ; Ho KW; Chiu NT
    PLoS One; 2019; 14(1):e0210055. PubMed ID: 30615636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy.
    Chang S; Koo PJ; Kwak JJ; Kim SJ
    Oncology; 2016; 90(2):97-102. PubMed ID: 26771676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and predictive values of interim
    Han S; Kim YI; Woo S; Kim TH; Ryu JS
    Ann Nucl Med; 2021 Apr; 35(4):447-457. PubMed ID: 33471289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of
    Iqbal SA; Goel S; Aggarwal A; Gupta N; Gupta M; Durga G; Talwar V; Singh S
    J Gastrointest Cancer; 2021 Sep; 52(3):1073-1080. PubMed ID: 33128717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography.
    Kato H; Fukuchi M; Miyazaki T; Nakajima M; Tanaka N; Inose T; Kimura H; Faried A; Saito K; Sohda M; Fukai Y; Masuda N; Manda R; Ojima H; Tsukada K; Oriuchi N; Endo K; Nonaka T; Shioya M; Ishikawa H; Sakurai H; Nakano T; Kuwano H
    Anticancer Res; 2007; 27(4C):2627-33. PubMed ID: 17695425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer: A prospective cohort study.
    Hagen PV; Heijl MV; van Berge Henegouwen MI; Boellaard R; Bossuyt PM; Kate FJ; Dekken HV; Hoekstra OS; Sloof GW; Lanschot JJ
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.